(November 24, 2020, Hong Kong) Kintor Pharmaceutical Limited (stock code: 9939, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) announced that the Company’s Suzhou Industrialisation Base was granted the Pharmaceutical Production License issued by Jiangsu Medical Products Administration, which is intended for the clinical samples and commercial mass production for its independent innovation and development of anti-tumor new pharmaceutical preparations (tablets) with an annual production capacity of 4 million tablets.

The Company’s R&D center and industrialisation base are located at No. 20 Songbei Road, industrial park area, Suzhou, covering an area of approximately 20,000 square meters, with a total investment of approximately RMB200 million. It officially commenced operation on 28 August 2020. The project design meets the requirements of cGMP from NMPA and FDA, and is equipped with first-class production facilities, equipment and inspection instruments at home and abroad.

Dr. Tong Youzhi, founder, Chairman and CEO of Kintor Pharmaceutical, said, “I am glad that the industrialisation base of Kintor Pharmaceutical was granted the Pharmaceutical Production License, symbolising another solid step for the Company’s industrialisation development to realise additional impetus for the new transformation. The Company will continue to work hard to achieve the commercialisation of manufacture of products as soon as practicable, and accelerate our progress to better meet the clinical needs of patients.”